Bristol-Myers Squibb Company
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
Last updated:
Abstract:
Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
Status:
Grant
Type:
Utility
Filling date:
13 Sep 2017
Issue date:
23 Jun 2020